{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Resistant Hypertension. Target Aldosterone. Transform Care \ud83d\ude80","description":"Resistant hypertension remains one of the most stubborn challenges in cardiovascular medicine. &amp;nbsp; The Bax24 phase 3 trial, published in The Lancet (2026), evaluated baxdrostat, a selective aldosterone synthase inhibitor, in patients already receiving multiple antihypertensive agents. &amp;nbsp; Key findings: \u2022 \u221216.6 mmHg reduction in 24-hour ambulatory SBP \u2022 \u221214.0 mmHg placebo-corrected difference (p&amp;lt;0.0001) \u2022 71% achieved BP control (&amp;lt;130 mmHg) vs 17% placebo \u2022 Acceptable safety profile, with hyperkalemia in 3% &amp;nbsp; These data highlight the growing importance of aldosterone dysregulation in resistant hypertension and suggest that targeted aldosterone synthase inhibition may represent a new therapeutic frontier. &amp;nbsp; Reference: Azizi M et al. Effect of Baxdrostat on Ambulatory Blood Pressure in Resistant Hypertension (Bax24). Lancet 2026. ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40348495\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/199345375"}